Therefore, an improved agent for the treatment of HER2-dependent breast cancer would inactivate EGFR, HER2, and HER3 in parallel, be effective in the treatment of cancer as a single agent, and be mechanistically complementary with the HER2-targeted monoclonal antibodies and tyrosine kinase inhibitors. This evidence concerns the gene ERBB3 and cancer.